Table 1.

Plasma total IgG pharmacokinetic data for intravenous and subcutaneous IGIV-C in patients with PIDD.^*

Parameter	Intravenous IGIV-C (n = 32)	Subcutaneous IGIV-C (n = 26)
AUC0-τ, mg h/ml, mean	7640	6858†
Cmax, mg/ml, mean ± s.d.	21·1 ± 3·9	12·2 ± 2·4
Ctrough, mg/ml, mean ± s.d.	9·6 ± 2·1‡	11·4 ± 2·3§
Cave, mg/ml, mean ± s.d.	n.d.	11·6 ± 2·4
tmax, h, mean ± s.d.	2·9 ± 1·1	55·0 ± 48·6
t1/2, h, mean ± s.d.	735·5 ± 138·5	n.d.¶

^*Data are reported for the pharmacokinetic population, with the exception of C_trough data (IgG population).

^†Adjusted steady-state AUC based on intravenous dosing schedule (every 3 versus 4 weeks).

^‡Mean C_trough for intravenous IGIV-C was calculated from data for two intravenous infusions.

^§Mean C_trough for subcutaneous IGIV-C was calculated from data for weeks 13, 17, 18, 19 and 21 for 28 patients (all patients who received study medication and had C_trough data).

^¶Not determined because of relatively constant plasma concentrations over 7-day dosing interval. AUC_0-τ, area under the concentration-versus-time curve over the dosing interval; C_ave, mean steady-state IgG concentration; C_max, maximum observed IgG concentration; C_trough, trough (predose) plasma IgG concentration; IgG, immunoglobulin G; IGIV-C, immune globulin intravenous (human), 10% caprylate/chromatography purified; n.d., not determined; PIDD, primary immunodeficiency disease; s.d., standard deviation; t_1/2, apparent elimination half-life; t_max, time to C_max.